This article was originally published in The Gray Sheet
Executive SummaryTUNA developer raises $16.5 mil. via direct placement with institutional purchasers and private investors of more than 4.3 mil. shares of common stock priced at about $3.84 per share. The firm also issues warrants for purchasers to buy about 1.1 mil. shares of common stock at $5 per share through May 20, 2001. The capital infusion will be used to "fund ongoing operations" and enable management to increase public awareness and gain approval by state governments to reimburse for benign prostatic hyperplasia procedures involving the firm's transurethral needle ablation (TUNA) system. VidaMed, which introduced the 510(k)-cleared TUNA platform in October 1996 ("The Gray Sheet" Oct. 14, 1996, I&W-4), is launching at the American Urology Association meeting the week of May 31 the PROVu TUNA system. Comprised of a reusable handle, disposable cartridge and telescope, PROVu facilitates access to the middle and lateral-prostatic lobes for TUNA treatment. The system was 510(k)-cleared in November, the company says
You may also be interested in...
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.